Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

An isolated antigen-binding protein characterised in that it is capable of binding specifically to human Arginase II (ARG2) and inhibiting the enzyme activity of human ARG2.

The present invention provides bispecific antigen-binding molecules characterized by comprising a first and a second domain, each binding to any of CS1, BCMA, CD20, CD22, FLT3, CD123, CLL1, MSLN, CDH3 or EpCAM, a third domain binding to an extracellular epitope of the human and the Macaca CD3ε chain and optionally a fourth domain, which is a Fc modality. Moreover, the invention provides a polynucleotide, encoding the antigen-binding molecule, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

The present application relates to anti-TIGIT antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of infectious diseases and cancer.

Provided are anti-PD-L1 antibodies. It also provides the nucleic acid molecules encoding the anti-PD-L1 antibodies, expression vectors and host cells used for the expression of the anti-PD-L1 antibodies. It also provides the methods for producing the anti-PD-L1 antibodies and the use thereof.

Provided are anti-CD47 antibodies, the nucleic acid molecules encoding the anti-CD47 antibodies, expression vectors and host cells used for the expression of anti-CD47 antibodies. Provided are methods for validating the function of antibodies. The antibodies provide a potent agent for the treatment of cancers via modulating immune functions.

Provided are an anti-RS virus antibody with high sensitivity and a test reagent using the antibody.

An anti-RS virus N protein monoclonal antibody or an antigen-binding fragment thereof, which is characterized in that it reacts with peptides consisting of the amino acid sequences as set forth in, at least, SEQ ID NOs: 30, 39, 40, 69, 70, 74, 75, 83, 84, 100, 101, and 113, among 127 peptide spots produced based on the amino acid sequence of the N protein of an RS virus.

Provided are anti-CD137 constructs that bind to CD137, including multispecific anti-CD137 antibodies with binding specificity for CD137 and one or more additional antigens, and methods of using the same. In certain embodiments, the one or more additional antigens comprise human epidermal growth factor receptor 2 (HER2).

The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.